Avidity Biosciences, Inc.RNANASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -17.10% | +35.57% | -55.60% | +88.12% | +434.03% |
| Gross Profit Growth | +0.00% | +88.40% | -45.80% | -9987.92% | +434.03% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +66.50% | +68.96% | +48.18% | +21.22% | +11.77% |
| Weighted Average Shares Diluted Growth | +66.50% | +68.96% | +48.18% | +21.22% | +11.77% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | -705.24% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | -763.68% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +1821.00% | +227.29% | +304.67% | -45.65% | -21.72% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +186.27% | +148.81% | +53.35% | +1.60% | +30.07% |
| Book Value per Share Growth | +74.49% | +68.42% | +7.92% | -19.42% | +12.26% |
| Debt Growth | -28.16% | -30.97% | -34.69% | -38.74% | +557.36% |
| R&D Expense Growth | +61.79% | +81.05% | +48.87% | +116.02% | +100.72% |
| SG&A Expenses Growth | +69.52% | +82.78% | +153.45% | +77.82% | +99.08% |